This week, the U.K. National Institute for Health and Care Excellence blessed Pfizer's kidney cancer treatment Inlyta, changed its mind in support of Bayer's prostate cancer therapy Xofigo, and backed Boehringer Ingelheim's anticoagulant Pradaxa for blood clots in the legs and lungs.
Pfizer has run into the U.K. watchdog wall of resistance to targeted cancer drugs with its renal cancer treatment Inlyta.
The FDA gave its blessing to Bosulif, a treatment for chronic myelogenous leukemia (CML) patients with Philadelphia chromosome-positive disease. It's a second-line approval, for patients who've failed on--or can't tolerate--another drug. Analysts figure the approval is worth $341 million in annual sales by 2016, Reuters reports.
E.U. regulators have recommended Pfizer's kidney cancer drug Inlyta be approved for use in patients who don't respond to other medications.
Pfizer's ($PFE) cancer drug team nailed a unanimous endorsement from an FDA expert panel this morning following its review of axitinib, setting it on a path to a likely approval for patients with